Related Experiment Video
Updated: May 24, 2026

Optogenetic Phase Transition of TDP-43 in Spinal Motor Neurons of Zebrafish Larvae
Published on: February 25, 2022
Structural dynamics associated with intermediate formation in an archetypal conformational disease.
Mun Peak Nyon1, Lakshmi Segu, Lisa D Cabrita
1Institute of Structural and Molecular Biology, Department of Biological Sciences, Birkbeck College, London, WC1E 7HX, UK.
Mild protein variants, like Lys154Asn alpha-1-antitrypsin, can model conformational diseases. Studying these intermediates using nuclear magnetic resonance reveals structural insights without unfolding, aiding disease understanding.
Area of Science:
- Biochemistry
- Structural Biology
- Biophysics
Background:
- Conformational diseases involve protein misfolding and polymerization.
- Characterizing unstable, low-abundance intermediates is analytically challenging.
- A specific variant, Lys154Asn α(1)-antitrypsin, mimics in vivo polymer formation.
Purpose of the Study:
- To structurally and dynamically characterize a mild α(1)-antitrypsin variant (Lys154Asn) that forms polymers.
- To investigate the nature of the disease-relevant intermediate under physiological conditions.
- To explore regulatory interactions governing protein conformational change.
Main Methods:
- Nuclear magnetic resonance (NMR) spectroscopy was employed.
- Characterization was performed on the Lys154Asn α(1)-antitrypsin variant.
- Studies utilized physiological temperatures and minimally perturbing techniques.
Main Results:
- Lys154Asn α(1)-antitrypsin populates a polymerization intermediate ensemble at physiological temperatures.
- NMR data revealed structural and dynamic changes associated with this intermediate.
- The findings suggest a specific interaction network regulates conformational change, refuting substantial unfolding of the intermediate.
Conclusions:
- Mild disease variants and minimally perturbing techniques are valuable for studying conformational disease intermediates.
- The disease-relevant intermediate of α(1)-antitrypsin is not substantially unfolded.
- Understanding these intermediates is crucial for developing therapeutic strategies for conformational diseases.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Types of Intermediate Filaments
Degenerative Disc Disease I: Introduction
Formation of Intermediate Filaments
Degenerative Disc Disease ll: Pathophysiology
